Outbreak of measles among persons with prior evidence of immunity, New York City, 2011

Clinical Infectious Diseases

Volumn 58, Issue 9, 2014, Pages 1205-1210

  Rosen, Jennifer B ^a   Rota, Jennifer S ^b   Hickman, Carole J ^b   Sowers, Sun B ^b   Mercader, Sara ^b   Rota, Paul A ^b   Bellini, William J ^b   Huang, Ada J ^c   Doll, Margaret K ^a   Zucker, Jane R ^a,b   Zimmerman, Christopher M ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c Westchester Co Department of Health   (United States)

Author keywords

immunity; measles; outbreak; vaccine failure; waning immunity

Indexed keywords

IMMUNOGLOBULIN G; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; NEUTRALIZING ANTIBODY; IMMUNOGLOBULIN M; MEASLES VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; CASE REPORT; COMMON COLD; CONJUNCTIVITIS; COUGHING; DRUG ERUPTION; DRUG FEVER; EMERGENCY WARD; FEMALE; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEASLES; MEASLES VACCINATION; MEDICAL CARE; MEDICAL HISTORY; MITRAL VALVE PROLAPSE; PRIORITY JOURNAL; SECONDARY IMMUNE RESPONSE; SORE THROAT; UNITED STATES; VIRUS IMMUNITY; YOUNG ADULT; AGED; ANTIBODY AFFINITY; BLOOD; EPIDEMIC; IMMUNOLOGY; MIDDLE AGED; TRANSMISSION; VACCINATION;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; DISEASE OUTBREAKS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEASLES; MEASLES VACCINE; MIDDLE AGED; NEW YORK CITY; VACCINATION;

EID: 84898903287     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu105     Document Type: Article

References (40)

1. Langmuir A. Medical importance of measles. Am J Dis Child 1962; 103:54-6
2. Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J Infect Dis 2004; 189(suppl 1):S1-3
3. Centers for Disease Control and Prevention. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998; 47:1-57
4. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among children aged 19-35 months - United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:689-96
5. Katz S, Hinman A. Summary and conclusions: Measles elimination meeting 16-17 March 2000. J Infect Dis 2004; 189(suppl 1):S43-7
6. Centers for Disease Control and Prevention. Measles - United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:253-7
7. Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:1-34
8. Ammari L, Bell L, Hodinka R. Secondary measles vaccine failure in healthcare workers exposed to infected patients. Infect Control Hosp Epidemiol 1993; 14:81-6
9. Atrasheuskaya A, Kulak M, Neverov A, Rubin S, Ignatyev G. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005. Vaccine 2008; 26:2111-8
10. Coleman K, Markey P. Measles transmission in immunized and partially immunized air travellers. Epidemiol Infect 2010; 138:1012-5
11. Edmonson M, Addiss D, McPherson J, Berg J, Circo S, David J. Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. JAMA 1990; 263:2467-71
12. Hickman CJ, Hyde TB, Sowers SB, et al. Laboratory characterization of measles virus infection in previously vaccinated and unvaccinated individuals. J Infect Dis 2011; 204(suppl 1):S549-58
13. Rota JS, Hickman CJ, Sowers SB, Rota PA, Mercader S, Bellini WJ. Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: High risk of infection but low risk of transmission. J Infect Dis 2011; 204(suppl 1):S559-63
14. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: Reevaluation of protective titers. J Infect Dis 1990; 162:1036-42
15. Haralambieva IH, Ovsyannikova IG, O'Byrne M, Pankratz VS, Jacobson RMPoland GA. A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine 2011; 29:4485-91
16. Haralambieva IH, Ovsyannikova IG, Pankratz VS, Kennedy RB, Jacobson RM, Poland GA. The genetic basis for interindividual immune response variation to measles vaccine: New understanding and new vaccine approaches. Expert Rev Vaccines 2013; 12:57-70
17. LeBaron CW, Beeler JA, Sullivan BJ, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007; 161:294-301
18. Poland G, Jacobson R, Thampy A, et al. Measles reimmunization in children seronegative after initial immunization. JAMA 1997; 277:1156-8
19. Centers for Disease Control and Prevention. Measles vaccine efficacy - United States. MMWR Morb Mortal Wkly Rep 1980; 29:470-2
20. Mossong J,Muller C.Modelling measles re-emergence as a result of waning of immunity in vaccinated populations. Vaccine 2003; 21:4597-603
21. Pebody RG, Gay NJ, Hesketh LM, et al. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine 2002; 20:1134-40
22. CSTE position statement 09-ID-48: Public health reporting and national notification for measles. Available at: Http://c.ymcdn.com/sites/www. cste.org/resource/resmgr/PS/09-ID-48.pdf. Accessed 8 March 2014
23. Hummel KB, Erdman DD, Heath J, Bellini WJ. Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays. J Clin Microbiol 1992; 30:2874-80
24. Erdman DD, Heath JL, Watson JC, Markowitz LE, Bellini WJ. ImmunoglobulinMantibody response to measles virus following primary and secondary vaccination and natural virus infection. J Med Virol 1993; 41:44-8
25. Mercader S, Garcia P, Bellini W. Measles IgG avidity assay: Use in classification of measles vaccine failure cases in elimination settings. Clin Vaccine Immunol 2012; 19:1810-7
26. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 1981; 3:251-60
27. Lennette EH, Schmidt N. Diagnostic procedures for viral and rickettsial infections. 5th ed. Washington, DC: American Public Health Association, 1979
28. Cohen B, Audet S, Andrews N, Beeler J. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 2007; 26:59-66
29. Hummel KB, Lowe L, Bellini WJ, Rota PA. Development of quantitative gene-specific real-Time RT-PCR assays for the detection of measles virus in clinical specimens. J Virol Methods 2006; 132:166-73
30. Rota PA, Brown KE, Hubschen JM, et al. Improving global virologic surveillance for measles and rubella. J Infect Dis 2011; 204(suppl S1):506-13
31. Rota P, Brown K, Mankertz A, et al. Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis 2011; 204 (suppl 1):S514-23
32. World Health Organization. Measles virus nomenclature update: 2012. Wkly Epidemiol Rec 2012; 87:73-81
33. Yeung LF, Lurie P, Dayan G, et al. A limited outbreak in a highly vaccinated US boarding school. Pediatrics 2005; 116:1287-91
34. Gans H, Yasukawa L, Alderson A, et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 2004; 190:83-90
35. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001; 184:817-26
36. Strebel P, Papania M, Fiebelkorn A, Halsey N. Measles vaccine. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines. Philadelphia: Elsevier, 2012:352-87
37. Ward B, Boulianne N, Ratnam S, Gulot M-C, Couillard M, DeSerres G. Cellular immunity in measles vaccine failure: Demonstration of measles antigen-specific lymphoproliferative responses despite limited serum production after revaccination. J Infect Dis 1995; 172:1591-5
38. Pichichero M. Booster vaccinations: Can immunologic memory outpace disease pathogenesis?. Pediatrics 2009; 124:1633-41
39. Mossong J, Nokes D, Edmunds W, Cox M, Ratnam S, Muller C. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am J Epidemiol 1999; 150:1238-49
40. van den Hof S, Berbers G, de Melker H, Conyn-van Spaendonck M, Marin M. Sero-epidemiology of measles antibodies in the Netherlands, a cross-sectional study in a national sample and in communities with low vaccine coverage. Vaccine 1999; 18:931-40.